Australia's most trusted
source of pharma news
Friday, 09 January 2026
Posted 8 March 2021 AM
The TGA has approved two of Novartis' major therapies, single shot gene therapy Zolgensma and multiple sclerosis treatment Kesimpta.
At US$ 2 million a dose, Zolgensma is the most expensive drug in the world and was deferred by PBAC at its November meeting last year.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.